Capital
Empowering success through innovative alliances
As cost pressures have made your old business model untenable, both big pharmaceutical and emerging biotech companies are looking for new ways to shift the costs and mitigate risks.
Our capital discipline manages an emerging area of bio pharma – non-traditional alliances.
By partnering with you early on, and investing our human, intellectual and financial capital in drug development and commercialization, both Quintiles and its bio pharmaceutical partners have clear incentives to achieve the same positive outcomes. Our non-traditional alliances help you to:
- make fixed costs variable
- increase pipeline throughput
- align partnership risk and rewards
The end goal: accelerate outcomes.
Non-Traditional Partnership Models
- Investment partnering/structured finance – underwriting (including due diligence) and structuring risk based partnerships
- Strategic resourcing – structured non-traditional service partnerships
- Joint development – shared development investments and rewards
- Emerging businesses – driving differential service offering for small bio pharma companies
- Managed Partnerships
-
Support your business initiative with resources and expertise.
- Outsourcing
-
Transform large fixed costs into variable as-needed resources.
- Biotech Relationships
-
Bring your project to market with top biotech specialists and virtual infrastructure.
- Government & Non-Profit
-
Navigate the political, cultural and geographic complexities in urban and isolated locations.
